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CORRESPONDENCE
Letters to the Editor
Is the Metabolic Syndrome
a Cardiovascular Risk Factor
Beyond Its Specific Components?
The discussion about the cardiovascular risk conferred by the
metabolic syndrome (MetSyn) is an actual topic, and we read the
meta-analysis about this argument published by Gami et al. (1)
with interest. A crucial point concerns the following question: is
the risk associated with the MetSyn greater (synergic) than the
sum of the risk components conferred by the individual factors that
define the syndrome? If the answer is yes, the MetSyn should be
recognized as a specific entity and taken into account for correct
evaluation of cardiovascular risk; whereas if the answer is no, it
should be sufficient to treat the individual factors of the MetSyn
without paying attention to its presence.
Even if the results reported in the study’s abstract (1) correctly
affirm that the MetSyn predicts cardiovascular events after adjust-
ment for traditional cardiovascular risk factors, the message re-
ported in the text is different. In fact, Gami et al. (1) affirm that the
MetSyn increases “risk of cardiovascular disease or death. . ., even
after controlling for its component risk factors,” thus reinforcing
this concept in the Discussion section where they state that “the
analysis. . .demonstrates that the MetSyn confers cardiovascular
risk beyond that which is associated with its component risk
factors” and concluding that “in addition to targeting individual
cardiovascular risk factors primary prevention trials should study
interventions that address the MetSyn as one entity.” The datum
supporting these assertions was the meta-analysis of three studies
(2–4) that adjusted the risk conferred by the MetSyn for several
traditional risk factors but not for the specific components of the
MetSyn.
Moreover, careful analysis of the three studies leads to a
different conclusion. In the ARIC (Atherosclerosis Risk In Com-
munities) study, McNeill et al. (2) adjusted the risk associated with
the MetSyn for its components, reporting a hazard ratio (HR) of
coronary heart disease of 0.91 (95% confidence interval [CI] 0.67
to 1.23) for men and 0.71 (95% CI 0.45 to 1.14) for women,
“indicating that the risk of coronary heart disease associated with
the syndrome was not in excess of the level explained by the
presence of its individual components.” In the WOSCOPS (West
of Scotland Coronary Prevention Study), Sattar et al. (3) affirm
that “possession of the MetSyn was not a significant predictor in
the presence of the effects of its individual components when
investigated in a multivariate model.”
Finally, Schillaci et al. (4) reported an HR associated with the
MetSyn of 1.73 (95% CI 1.25 to 2.38), after adjustment for blood
pressure as the only component of the MetSyn, without mention
of any analysis adjusting the risk associated with the MetSyn for its
specific components. In conclusion and in agreement with recent
observations (5,6), no study cited supports a synergic effect of the
individual factors of the MetSyn on cardiovascular risk, excluding,
at the moment, the necessity to consider the MetSyn as a specific
cardiovascular risk factor beyond its components.
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Reply
We appreciate the comments of Dr. Inchiostro and colleagues
regarding one of the more controversial topics regarding the
metabolic syndrome (MetSyn), namely whether it poses cardio-
vascular risk beyond what is already conferred by the cardiac risk
factors that comprise it. We attempted to address this question by
including in a single meta-analysis the results from individual
studies that had included MetSyn and its component risk factors
into the same multivariate model (1).
Sattar et al. (2) did report an effect estimate (hazard ratio [HR]
1.4; 95% confidence interval [CI] 1.05 to 1.89) from a multivariate
model that included the MetSyn, body mass index, blood pressure,
lipid abnormalities, glucose abnormalities, and C-reactive protein
(which represent the clustering of risk factors that comprise the
MetSyn), and we included this in the analysis (2).
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